Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL28730871 | 0.95 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL4810770 | 0.81 | CYP19A1 (0.60) | MAOB | |
| SCHEMBL2004098 | 0.81 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL105590 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL7305175 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL28393152 | 0.80 | MAPK1 (0.53) | MAOB | |
| SCHEMBL11478353 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL5570294 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL4812324 | 0.75 | MAOB (0.49) | MAOB | |
| SCHEMBL72587 | 0.74 | MAOB (0.56) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104945456-A | 2-(1',2',3'-triazolyl-4'-oxymethylenepyridyl)-1,3,4,6-O-acetyl-D-glucose and its preparation method and use | UNIV HUBEI ENGINEERING | 2015-09-30 | — | — | CN | claimed |
| EP-0922050-B1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2003-07-30 | — | — | EP | claimed |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12522571-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11945786-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| CN-114409716-A | Sugar-modified metal helix complex, preparation method thereof and application of complex as amyloid degradation device | 中国科学院长春应用化学研究所 | 2022-04-29 | — | — | CN | disclosed |
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| EP-0320992-B1 | Triazolodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 1994-07-27 | — | — | EP | disclosed |
| US-4959361-A | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists | HOFFMANN-LA ROCHE INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0320992-A2 | Triazolodiazepine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-06-21 | — | — | EP | disclosed |
| US-4220577-A | Iodopropargyl pyridyl and picolinyl ethers and thioethers as paint fungicides | GIVAUDAN CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| US-4170704-A | STABLE TO HEAT AND LIGHT | GIVAUDAN CORPORATION (US) | 1979-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | CHRNB2 1865/4885CHRNA4 1802/4885CHRNA3 1270/4885 |
| US-11945786-B2 | Compounds, devices, and uses thereof | SLC10A1, SLCO1B3, SLC5A1 | CHRNB2 1865/4885CHRNA4 1802/4885CHRNA3 1270/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | CHRNB2 4572/4885CHRNA4 4738/4885CHRNA3 4413/4885 |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | CHRNB2 1865/4885CHRNA4 1802/4885CHRNA3 1270/4885 |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | CHRNB2 3226/4885CHRNA4 3870/4885CHRNA3 3791/4885 |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | NR3C2, AGTR1, CHRM1 | CHRNB2 332/4885CHRNA4 507/4885CHRNA3 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.